Joined John Deere supply base and chosen to deploy DriveMod Tuggers to Dubuque, IA operation.Renewed contract with US Continental, unveiling a study that found Cyngn's autonomous vehicles yielded 4x efficiency gain.Announced initial deployment with Rivian.Announced strategic partnership with RobotLAB, expanding the Cyngn Distributor Network.Aligned with Nvidia to power DriveMod's artificial intelligence.Attended MODEX with Motrec, premiering the DriveMod Tugger autonomous MT-160. Secured our 19th granted US patent.Launched our "auto-unhitch" feature, enabling DriveMod Tuggers to drop off carts without requiring any human intervention.MENLO PARK, Calif., May 16, 2024 /PRNewswire/ -- Cyngn Inc. (the "Company" or "Cyngn") (Nasdaq: CYN) today shared several commercial and technological accomplishments ...

PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced it has closed its previously announced registered direct offering with healthcare-focused institutional investors and a certain existing investor and a director of the Company for the purchase and sale of 2,402,935 common shares of the Company (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 2,402,935 common shares of the Company for aggregate gross proceeds of ...

LAS VEGAS, May 16, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN) announced today it has closed its previously announced acquisition of blockchain financial technology provider, ALT 5 Sigma Inc., and each of its wholly-owned subsidiaries.

BEIJING, May 15, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced today the following: On April 12, 2024 CASI submitted the IND application to the FDA for CID-103 to support a phase 1/2 study of CID-103 in adults with chronic Immune Thrombocytopenia (ITP). On May 13, 2024 CASI received a letter from FDA indicating that study may proceed.